Active substance
Acetylsalicylic acid
- SFDA 27
- US FDA 5
- Health Canada 27
- US price lines 16
- NHS prices 10
- WHO EML 4
- Safety 13
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ASPICARD 81MG TAB | 81 mg | Enteric-coated tablet · Oral use | 120 Blister | SAR 30.00 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ASPIRIN ADULT TAB 300MG | 300 mg | Tablet · Oral use | 30 Blister | SAR 3.50 | Generic · OTC | BAYER CONSUMER CARE AG | Valid |
| ASPIRIN PROTECT 100MG E.C. TABLETS | 100 mg | Enteric-coated tablet · Oral use | 60 Blister | SAR 19.05 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| AZERA 100 mg enteric-coated tablet | 100 mg | Enteric-coated tablet · Oral use | 90 Tablet Container | SAR 6.35 | Generic · OTC | UNITED PHARMACEUTICAL CO. | Valid |
| DISPRIN | 81 mg | Enteric-coated tablet · Oral use | 100 Tablet Container | SAR 25.00 | Generic · OTC | RIYADH PHARMA | Valid |
| JUSPRIN 81MG ENTERIC COATED TABLETS | 81 mg | Enteric-coated tablet · Oral use | 30 Bottle | SAR 7.50 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Jusprin | 81 mg | Enteric-coated tablet · Oral use | 90 Bottle | SAR 22.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ADIPRIN 100MG E.C.TAB | 100 mg | Gastro-resistant coated tablet · Oral use | 30 Blister | SAR 2.35 | Generic · OTC | THE ARAB PHARMACEUTICAL MANUFACTURING PSC | Withdrawn by MAH · Not Marketed |
| ADIPRIN 100MG E.C.TAB | 100 mg | Gastro-resistant coated tablet · Oral use | 100 Blister | SAR 6.75 | Generic · OTC | THE ARAB PHARMACEUTICAL MANUFACTURING PSC | Withdrawn by MAH · Not Marketed |
| ASPICOT 100 MG E.C. TABLETS | 2 mg | Enteric-coated tablet · Oral use | 100 Blister | SAR 2.00 | Generic · OTC | PHARMALINE | Withdrawn by MAH · Not Marketed |
| ASPICOT 100 MG E.C. TABLETS | 100 mg | Enteric-coated tablet · Oral use | 30 Blister | SAR 0.70 | Generic · OTC | PHARMALINE | Withdrawn by MAH · Not Marketed |
| ASPIRIN ADULT TAB 300MG | 300 mg | Tablet · Oral use | 30 Blister | SAR 5.10 | Generic · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ASPIRIN CHILDREN 100mg | 100 mg | Tablet · Oral use | 30 Blister | SAR 4.00 | Generic · OTC | BAYER PHARMA AG | Suspended · Not Marketed |
| ASPIRIN PROTECT 100MG E.C. TABLETS | 100 mg | Film-coated tablet · Oral use | 20 Blister | SAR 6.35 | Generic · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ASPRO 320 MG TABLETS | 320 mg | Tablet · Oral use | 30 Blister | SAR 4.10 | Generic · OTC | BAYER SANTE FAMILIALE | Withdrawn by MAH · Not Marketed |
| ASPRO 320 MG TABLETS | 320 mg | Tablet · Oral use | 20 Blister | SAR 2.90 | Generic · OTC | BAYER SANTE FAMILIALE | Withdrawn by MAH · Not Marketed |
| HYPYRIN TAB 400MG | 400 mg | Tablet · Oral use | 100 Tablet Container | SAR 17.55 | Generic · Prescription | EISAI | Withdrawn by MAH · Not Marketed |
| JUSPRIN 300MG ENTERIC COATED TABLETS | 300 mg | Enteric-coated tablet · Oral use | 30 Blister | SAR 3.85 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| JUSPRIN 500MG ENTERIC COATED TABLETS | 500 mg | Enteric-coated tablet · Oral use | 20 Blister | SAR 4.05 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| KIDIPRIN CHEWABLE TABS 100MG | 100 mg | Chewable tablet · Oral use | 30 Blister | SAR 0.70 | Generic · OTC | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| NOVASEN 325MG E.C TAB | 325 mg | Gastro-resistant coated tablet · Oral use | 60 Blister | SAR 12.75 | Generic · OTC | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| NOVASEN 325MG E.C TAB | 325 mg | Gastro-resistant coated tablet · Oral use | 30 Blister | SAR 7.25 | Generic · OTC | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| NOVASEN 650MG E.C TAB | 650 mg | Gastro-resistant coated tablet · Oral use | 60 Blister | SAR 20.90 | Generic · Prescription | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| NOVASEN 650MG E.C TAB | 650 mg | Gastro-resistant coated tablet · Oral use | 30 Blister | SAR 11.95 | Generic · Prescription | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| REMIN TAB 300MG | 300 mg | Effervescent tablet · Oral use | 30 Blister | SAR 0.75 | NCE · OTC | APM | Withdrawn by MAH · Not Marketed |
2 more — full table
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ CARDIAC ARREST, CARDIOVASCULAR EMERGENCIES AND/OR DYSRHYTHMIAS; ANTIPHOSPHOLIPID SYNDROME; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); COLORECTAL CANCER-ADVANCED/ METASTATIC; CORONARY ARTERY DISEASE; DENTAL ABSCESS-DENTAL PAIN; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HIP AND KNEE REPLACEMENT SURGERY; HODGKIN'S LYMPHOMA; INFECTIOUS MONONUCLEOSIS; ISCHEMIC STROKE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MATERNAL AND CHILD HEALTHCARE- PERINATAL,INTRAPARTUM AND POSTPARTUM CARE-PRE-ECLAMPSIA; MULTIPLE MYELOMA; MYELOFIBROSIS-ADVERSE REACTION MANAGEMENT; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); PERICORONITIS; POLYCYTHEMIA VERA; PULMONARY EMBOLISM; SINUSITIS; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); SYSTEMIC LUPUS ERYTHEMATOSUS; T-CELL LYMPHOMA-RENAL TOXICITY; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM DISEASE (VTE)-PROPHYLAXIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VAZALORE | 325MG; 81MG | capsule · oral | PLX PHARMA | Over-the-counter | 14 Jan 2013 |
| 8-HOUR BAYER | 650MG | tablet, extended release · oral | BAYER | Discontinued | 25 Jun 1965 |
| MEASURIN | 650MG | tablet, extended release · oral | BAYER | Discontinued | 25 Jun 1965 |
| BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN | 500MG | tablet · oral | BAYER | Discontinued | 18 Oct 2001 |
| DURLAZA | 162.5MG | capsule, extended release · oral | HESP | Discontinued | 4 Sep 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ASA | 02433044 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| ASA 325MG | 00530336 | 325 MG | TABLET · ORAL | VITA HEALTH PRODUCTS INC |
| ASA 81 MG | 02244993 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| ASA 81 MG | 02372177 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | VITA HEALTH PRODUCTS INC |
| ASA DAILY LOW DOSE | 02394790 | 81 MG | TABLET (CHEWABLE) · ORAL | PHARMASCIENCE INC |
| ASAPHEN | 02009013 | 80 MG | TABLET (CHEWABLE) · ORAL | PHARMASCIENCE INC |
| ASAPHEN E.C. 80 MG | 02238545 | 80 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| ASPIRIN 81MG | 02237726 | 81 MG | TABLET (ENTERIC-COATED) · ORAL | BAYER INC |
| ASPIRIN 81MG QUICK CHEWS | 02289970 | 81 MG | TABLET (CHEWABLE) · ORAL | BAYER INC |
| ASPIRIN COATED FOR DELAYED RELEASE REGULAR STRENGTH | 02150417 | 325 MG | TABLET (DELAYED-RELEASE) · ORAL | BAYER INC |
| ASPIRIN EXTRA STRENGTH | 02150336 | 500 MG | TABLET · ORAL | BAYER INC |
| ASPIRIN REGULAR STRENGTH | 02150328 | 325 MG | TABLET · ORAL | BAYER INC |
| ENTERIC COATED DAILY LOW DOSE ASA 81 MG | 02363127 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | VITA HEALTH PRODUCTS INC |
| ENTROPHEN | 02242281 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| ENTROPHEN CHEWABLE | 02243974 | 81 MG | TABLET (CHEWABLE) · ORAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| JAMP-ASA 81MG EC | 02427206 | 81 MG | TABLET (ENTERIC-COATED) · ORAL | VITA HEALTH PRODUCTS INC |
| JAMP-ASA CHEW | 02269139 | 80 MG | TABLET (CHEWABLE) · ORAL | JAMP PHARMA CORPORATION |
| JAMP-ASA EC | 02283905 | 80 MG | TABLET (DELAYED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| M-ASA 80 MG CROQUABLE | 02429950 | 80 MG | TABLET (CHEWABLE) · ORAL | MANTRA PHARMA INC |
| PRAXIS ASA EC 81 MG DAILY LOW DOSE | 02283700 | 81 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PRO-AAS - 80 (CROQUABLE) | 02311518 | 80 MG | TABLET (CHEWABLE) · ORAL | PRO DOC LIMITEE |
| PRO-AAS EC - 80 | 02311496 | 80 MG | TABLET (DELAYED-RELEASE) · ORAL | PRO DOC LIMITEE |
| REGULAR STRENGTH ASA | 02551217 | 325 MG | TABLET · ORAL | LNK INTERNATIONAL INC. |
| RIVASA 80 MG EC | 02485222 | 80 MG | TABLET (DELAYED-RELEASE) · ORAL | LABORATOIRE RIVA INC. |
| RIVASA 80MG CROQUABLE - TAB | 02202352 | 80 MG | TABLET (CHEWABLE) · ORAL | LABORATOIRE RIVA INC. |
2 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ASPIRIN 325 MG TABLET | $0.0166 | per EA | 23 Sep 2026 |
| US NADAC | ASPIRIN 81 MG CHEWABLE TABLET | $0.02571 | per EA | 23 Sep 2026 |
| US NADAC | ASPIRIN EC 325 MG TABLET | $0.02216 | per EA | 23 Sep 2026 |
| US NADAC | ASPIRIN EC 81 MG TABLET | $0.01418 | per EA | 23 Sep 2026 |
| US NADAC | FT ASPIRIN 325 MG TABLET | $0.0166 | per EA | 23 Sep 2026 |
| US NADAC | FT ASPIRIN 81 MG CHEWABLE TAB | $0.02571 | per EA | 23 Sep 2026 |
| US NADAC | FT ASPIRIN EC 325 MG TABLET | $0.02216 | per EA | 23 Sep 2026 |
| US NADAC | FT ASPIRIN EC 81 MG TABLET | $0.01418 | per EA | 23 Sep 2026 |
| US NADAC | GNP ASPIRIN 325 MG TABLET | $0.0166 | per EA | 23 Sep 2026 |
| US NADAC | GNP ASPIRIN EC 81 MG TABLET | $0.01418 | per EA | 23 Sep 2026 |
| US NADAC | GS ASPIRIN 81 MG CHEWABLE TAB | $0.02571 | per EA | 23 Sep 2026 |
| US NADAC | QC ASPIRIN 325 MG TABLET | $0.0166 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Aspirin 150mg suppositories | £28.97 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 300mg dispersible tablets | £0.94 | 32 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 300mg gastro-resistant tablets | £72.08 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 300mg suppositories | £55.68 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 300mg tablets | £0.87 | 32 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 300mg tablets | £2.73 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 75mg dispersible tablets | £2.58 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 75mg dispersible tablets | £9.21 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 75mg gastro-resistant tablets | £2.12 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 75mg tablets | £2.12 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.5.1. Medicines for acute migraine attacks · core
Migraine
Oral > Solid: 300 to 500 mg - 12.5.1. Anti-platelet medicines · core
Acute myocardial infarction; Cerebral ischaemic stroke
Oral > Solid: 100 mg - 29.3. Medicines for juvenile joint diseases · complementary
Mucocutaneous lymph node syndrome; Juvenile idiopathic arthritis; Acute rheumatic fever without mention of heart involvement
Local > Rectal > Suppository: 150 mg; 300 mg | Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg | Oral > Solid > tablet: 75 to 500 mg - 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) · core
Pain
Oral > Solid: 100 to 500 mg | Local > Rectal > Suppository: 50 to 150 mg
Safety signals and safety-related labeling changes
- US FDA 22 Dec 2025 PERCODAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 SYNALGOS-DC — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 YOSPRALA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 EQUAGESIC — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 16 Nov 2021 VAZALORE — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 3 Nov 2021 EXCEDRIN (MIGRAINE) — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 13 May 2021 AGGRENOX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 FIORINAL W/CODEINE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 FIORINAL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 NORGESIC — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 NORGESIC FORTE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 17 Jan 2019 PRAC signal: Evaluation of data on cancer-related mortality from a single study in elderly adults
Action for MAH: update of the product information: No - MHRA 3 Oct 2009 Aspirin: not licensed for primary prevention of thrombotic vascular disease
In the UK, low-dose aspirin is licensed for prevention of thrombotic cerebrovascular or cardiovascular disease only in those who already have vascular disease—ie, secondary prevention.
Combinations containing Acetylsalicylic acid
- Acetylsalicylic acid + ascorbic acid
- Acetylsalicylic acid + caffeine
- Acetylsalicylic acid + clopidogrel
- Acetylsalicylic acid + codeine
- Acetylsalicylic acid + diethylamine
- Acetylsalicylic acid + methocarbamol
- Acetylsalicylic acid + oxycodone
- Acetylsalicylic acid + sodium bicarbonate
- Acetylsalicylic acid + butalbital + caffeine
- Acetylsalicylic acid + butalbital + caffeine + codeine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.